#ADA2021
1/6
✅Real world data from a 🇩🇪register of patients with ♂️#hypogonadism & #type2diabetes over 12 years!
❗️ ♂️ hypogonadism is common in T2D (≈ 50%)
⚠️@Bayer presented
⚠️ other data shown ⤴️ MACE
amjmed.com/article/S0002-…
So what did they find?
1/6
✅Real world data from a 🇩🇪register of patients with ♂️#hypogonadism & #type2diabetes over 12 years!
❗️ ♂️ hypogonadism is common in T2D (≈ 50%)
⚠️@Bayer presented
⚠️ other data shown ⤴️ MACE
amjmed.com/article/S0002-…
So what did they find?
2/6
Baseline Characteristics.
🤔As you can see two very different cohorts of patients.
⚠️ High risk of unresolved bias
Baseline Characteristics.
🤔As you can see two very different cohorts of patients.
⚠️ High risk of unresolved bias
3/6
Changes in testosterone and glycaemic markers over time.
Testosterone therapy assoc with
⤴️ Testosterone
⤵️ HbA1c
Changes in testosterone and glycaemic markers over time.
Testosterone therapy assoc with
⤴️ Testosterone
⤵️ HbA1c
4/6
Changes in weight and BP over time.
Testosterone therapy assoc with
⤵️ weight
⤵️ waist circumference
⤵️ BP
Changes in weight and BP over time.
Testosterone therapy assoc with
⤵️ weight
⤵️ waist circumference
⤵️ BP
5/6
Testosterone therapy in this cohort assoc with
⤵️ All-cause mortality
⤵️ myocardial infarction
⤵️ stroke
⤵️ retinopathy
⤵️ polyneuropathy
Testosterone therapy in this cohort assoc with
⤵️ All-cause mortality
⤵️ myocardial infarction
⤵️ stroke
⤵️ retinopathy
⤵️ polyneuropathy
My conclusions
Impressive data, particularly the 12 year follow up.
The two groups were quite different so impossible to eliminate residual bias.
We need an appropriately powered RCT to give us the information we need to counsel patients on the long-term effects.
Impressive data, particularly the 12 year follow up.
The two groups were quite different so impossible to eliminate residual bias.
We need an appropriately powered RCT to give us the information we need to counsel patients on the long-term effects.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
